Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Allogene Therapeutics (ALLO) Stock Price & Analysis
825 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.91 - $17.49
Previous Close$4.92
Volume416.09K
Average Volume (3M)1.89M
Market Cap
$746.03M
Enterprise Value$310.63M
Total Cash (Recent Filing)$517.32M
Total Debt (Recent Filing)$101.12M
Price to Earnings (P/E)-2.1
Beta1.41
Next Earnings
May 10, 2023EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding144,497,383
10 Day Avg. Volume1,712,141
30 Day Avg. Volume1,886,873
Standard Deviation0.20
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.09
Price to Sales (P/S)2925.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.28K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$17.87Price Target Upside253.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Allogene Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $4.91 and its highest was $17.49 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is May 10, 2023 which is in 42 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Feb 28, 2023. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.7 by $0.04.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.62.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 144,497,380 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.7. Following the earnings report the stock price went down -0.157%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 31M.
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.87 (253.86% Upside)
$17.87 (253.86% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Negative
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.37%
12-Months-Change
Fundamentals
Return on Equity
-42.04%
Trailing 12-Months
Asset Growth
-21.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
Top 5 ETFs holding ALLO
Simplify Propel Opportunities ETF
Fidelity Nasdaq Composite Index ETF
iShares U.S. Tech Breakthrough Multisector ETF
Direxion Fallen Knives ETF
BMO MSCI Innovation Index ETF
Up to five ETFs with an Outperform Smart Score that hold ALLO. The ETFs are listed according to market value of ALLO within the ETF
---
Day One Biopharmaceuticals
―
Springworks Therapeutics
―
Rhythm Pharmaceuticals
―
Twist Bioscience
―
Rocket Pharmaceuticals
―
---